N Engl J Med 2002; 346: 235–242 49 Pfreundschuh M, Trumper L, Os

N Engl J Med 2002; 346: 235–242. 49 Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391. 50 Spina M, Jaeger U, Sparano JA et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105: 1891–1897. 51 Levine AM, Noy A, Lee JY et al. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine,

and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin SB431542 Oncol 2013; 31: 58–64. 52 Ribera JM, Morgades M, Gonzalez-Barca E et al. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP. Br J Haematol 2012; 157: 637–639. 53 Strehl J, Mey U, Glasmacher A et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin’s lymphoma: a meta-analysis. Haematologica 2003; 88: 1304–1315. 54 Lim ST, Karim R, Nathwani BN et al. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J

Clin Oncol 2005; 23: 4430–4438. http://www.selleckchem.com/products/Roscovitine.html 55 Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483–1491. 56 Navarro JT, Ribera JM, Oriol A et al. Influence of highly active anti-retroviral therapy on response

to treatment and survival in patients with acquired immunodeficiency Edoxaban syndrome-related non-Hodgkin’s lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. B J Haematol 2001; 112: 909–915. 57 Vaccher E, Spina M, di Gennaro G et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155–163. 58 Hoffmann C, Wolf E, Fatkenheuer G et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17: 1521–1529. 59 Weiss R, Mitrou P, Arasteh K et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival–results of the German Multicenter Trial. Cancer 2006; 106: 1560–1568. 60 Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>